The European Commission has approved Pfizer’s Paxlovid for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe disease.
The decision to issue a conditional EU marketing authorization for Paxlovid, which consists of one tablet of nirmatrelvir (also known...








